The best treatment for amyloidosis depends entirely on which type you have. Amyloidosis isn’t a single disease. It’s a group of conditions where misfolded proteins build up in organs, and each type has a different source protein, a different mechanism, and a fundamentally different treatment strategy. The three most common forms are AL (light chain), ATTR (transthyretin), and AA (secondary) amyloidosis, and breakthroughs in the last few years have dramatically improved outcomes for the first two.
AL Amyloidosis: Targeting the Abnormal Plasma Cells
AL amyloidosis is caused by abnormal plasma cells in the bone marrow that produce misfolded light chain proteins. These proteins deposit in organs, most often the heart and kidneys. Treatment works by eliminating the rogue plasma cells, stopping the supply of damaging proteins at the source.
The current standard of care is a four-drug combination called Dara-CyBorD: daratumumab (an immunotherapy that targets a protein on the surface of plasma cells) combined with three other agents. It is the only FDA-approved first-line therapy for AL amyloidosis. In the landmark ANDROMEDA trial published in the New England Journal of Medicine, 53.3% of patients on Dara-CyBorD achieved a complete hematologic response, meaning the abnormal light chains became undetectable in their blood. That compared to just 18.1% for patients on the older three-drug regimen alone. At six months, organ recovery was also significantly better: 41.5% of patients showed cardiac improvement (versus 22.2%), and 53.0% showed kidney improvement (versus 23.9%).
The goal is typically to complete four to six cycles and reach at least a very good partial response, which means the harmful light chain levels have dropped dramatically. For patients who respond well enough and are healthy enough, autologous stem cell transplant remains a powerful option. Transplant eligibility generally requires adequate heart function, involvement of at least one major organ, and good overall physical condition. When patients qualify, transplant can deepen and extend remissions significantly.
How Staging Affects the Outlook
Doctors stage AL amyloidosis using blood markers that reflect how much strain the heart is under. The most widely used system looks at troponin (a marker of heart muscle damage) and NT-proBNP (a marker of heart wall stress). Patients caught at an early stage, before significant cardiac involvement, have a dramatically better prognosis. In advanced cases with very high NT-proBNP levels (above 8,500 ng/L), median survival can be as short as five months. When NT-proBNP stays below that threshold, even among patients staged as advanced, median survival stretches to nearly five years. This is why early detection and rapid treatment matter enormously in AL amyloidosis.
ATTR Amyloidosis: Stabilizers and Gene Silencers
ATTR amyloidosis is caused by transthyretin, a protein made in the liver that normally carries thyroid hormone and vitamin A through the bloodstream. When this protein becomes unstable, it breaks apart and refolds into amyloid fibrils that accumulate in the heart, nerves, or both. ATTR comes in two forms: hereditary (caused by a gene mutation) and wild-type (an age-related process, most common in men over 65). Treatment strategies fall into two categories, and some patients benefit from both.
TTR Stabilizers
These drugs work by binding to transthyretin and holding it in its normal, stable shape so it can’t break apart and misfold. Tafamidis is the most established option and the first drug approved specifically for ATTR cardiomyopathy. In clinical trials, tafamidis reduced the risk of death from any cause by 30% and cut cardiovascular hospitalizations by 32% over 30 months. Patients who started tafamidis early, before severe heart damage, saw the greatest benefit. Among those at the earliest disease stage, mortality dropped from 61% to 36% compared to placebo over the study’s follow-up period.
Acoramidis is a newer TTR stabilizer that binds the protein with even greater potency and has shown strong results in clinical trials for ATTR cardiomyopathy. Diflunisal, an older anti-inflammatory drug, also stabilizes transthyretin and is sometimes used off-label, particularly when other options are unavailable.
Gene-Silencing Therapies
Rather than stabilizing the protein, these treatments stop the liver from making transthyretin in the first place. They use a technology called RNA interference or antisense oligonucleotides to intercept the genetic instructions for transthyretin before the protein is ever produced. This reduces the amount of circulating transthyretin by roughly 80% or more.
Patisiran was the first RNA interference therapy ever approved by the FDA, initially for hereditary ATTR with nerve damage. Vutrisiran is its successor, requiring only one injection under the skin every three months instead of an intravenous infusion every three weeks. In clinical trials, vutrisiran significantly improved nerve function scores, walking speed, and quality of life in patients with hereditary ATTR polyneuropathy, with benefits sustained through 18 months. Inotersen and its next-generation version, eplontersen, work through a slightly different mechanism (antisense technology) but achieve the same result of shutting down transthyretin production in the liver.
For patients with ATTR cardiomyopathy specifically, the choice between a stabilizer and a gene silencer (or a combination) depends on disease severity, the presence of nerve involvement, and whether the condition is hereditary or wild-type. This is a rapidly evolving treatment landscape, and options that didn’t exist five years ago are now standard practice.
AA Amyloidosis: Treating the Root Cause
AA amyloidosis develops as a complication of chronic inflammatory diseases like rheumatoid arthritis, inflammatory bowel disease, chronic infections, or hereditary fever syndromes. The liver produces a protein called serum amyloid A during inflammation, and when inflammation persists for years, that protein can accumulate as amyloid deposits, most commonly in the kidneys.
The most effective treatment is aggressive control of the underlying inflammatory condition. When inflammation is suppressed and serum amyloid A levels drop, amyloid deposition can stabilize and even partially reverse over time. This means the “best treatment” for AA amyloidosis is highly individual. It could be biologic therapy for rheumatoid arthritis, surgery for a chronic abscess, or anti-inflammatory drugs for a hereditary fever syndrome. The specific amyloid deposits are not targeted directly. Instead, cutting off the supply of the precursor protein is what works.
Supportive Care for Organ Damage
Regardless of the type, amyloidosis often requires treatment for the organ damage it has already caused, alongside the disease-directed therapy. Heart involvement may call for careful fluid management and medications to control heart failure symptoms, though some standard heart failure drugs are poorly tolerated in amyloidosis and require adjustment. Kidney involvement often means dietary changes: limiting protein, sodium, and phosphorus intake to reduce strain on damaged kidneys. Some patients eventually need dialysis or, rarely, organ transplantation if a single organ bears the brunt of the damage and the underlying amyloid-producing process is well controlled.
Nerve damage from ATTR amyloidosis can cause numbness, pain, digestive problems, and drops in blood pressure upon standing. These symptoms are managed individually with medications for nerve pain, compression stockings, and dietary adjustments for gastrointestinal symptoms.
Therapies Targeting Existing Amyloid Deposits
Most current treatments focus on stopping new amyloid from forming, but they don’t directly clear deposits already lodged in organs. Several antibody-based therapies are in clinical trials that aim to fill this gap. Birtamimab is a monoclonal antibody that binds to AL amyloid fibrils and has been shown to be safe in early-phase trials. Anselamimab (CAEL-101) is another antibody in Phase III trials for AL amyloidosis, designed to help the body’s immune system recognize and remove existing amyloid deposits. If these therapies prove effective, combining deposit-clearing antibodies with the cell-killing or protein-silencing drugs already in use could significantly improve organ recovery.